## **WEST Search History**

Hide Items Restore Clear Cancel

DATE: Monday, November 22, 2004

Hide?	Set Name	Query	Hit Count			
	DB=PGPB	B, USPT, USOC, EPAB, JPAB, DWPI; THES=ASSIGNEE; PLUR=YES	; OP=ADJ			
	L11	L7.clm.	. 10			
	L10	L8.clm.	2			
	L9	L8.clm.	2			
	L8	L7 same (screen\$ or modulat\$ or identif\$)	217			
	L7	12 same (growth\$ or proliferation or apoptosis or death)	671			
	L6	l2 (s) (growth\$ or proliferation or apoptosis or death)	0			
DB=USPT; THES=ASSIGNEE; PLUR=YES; OP=ADJ						
.,,,,,,	L5	L4.clm.	3			
	L4	L2 same (screen\$ or identif\$)	66			
$DB=PGPB, USPT, USOC, EPAB, JPAB, DWPI; \ THES=ASSIGNEE; \ PLUR=YES; \ OP=ADJ$						
	L3	L2 same (screen\$ or identif\$)	384			
	L2	Perlecan or HSPG or syndecan or glypican	1261			
	L1	PILLARISETTI-SIVARAM.in.	23			

END OF SEARCH HISTORY







**Entrez** 

PubMed

Nucleotide

Protein

• Click on query # to add to strategy

Genome

• Search History will be lost after eight hours of inactivity.

Structure

**OMIM** 

**PMC** 

Journals

Preview

Bot

Search PubMed

for hurt-camejo 1997

To combine searches use # before search number, e.g., #2 AND #6.

Search numbers may not be continuous; all searches are represented.

Clipboard

Limits

Preview/Index

History

Details

**About Entrez** 

**Text Version** 

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

**PubMed Services** Journals Database MeSH Database Single Citation Matcher **Batch Citation Matcher** Clinical Queries LinkOut Cubby

Related Resources **Order Documents NLM Catalog NLM Gateway TOXNET** Consumer Health **Clinical Alerts** ClinicalTrials.gov PubMed Central

Search	<b>Most Recent Queries</b>	Time	Result
<u>#18</u>	Search hurt-camejo 1997	09:43:54	<u>6</u>
<i>#</i> 17	Search hurt cameio 1997	09:43:41	<u>120</u>
<u>#10</u>	Related Articles for PubMed (Select 10593935)	09:07:33	<u>289</u>
<u>#9</u>	Search pillarisetti 36403	09:06:15	1
<u>#7</u>	Search Pillarisetti 36403	08:30:39	1
#4	Related Articles for PubMed (Select 9496392)	08:20:11	<u>221</u>
<u>#1</u>	Search Adatia 1257	07:59:45	1

Clear History

Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Privacy Statement | Freedom of Information Act | Disclaimer

Nov 16 2004 07:00:47

cb

L2

L3

L5

Lб

≂>

(FILE 'HOME' ENTERED AT 09:55:47 ON 22 NOV 2004)

FILE 'DISSABS, 1MOBILITY, AGRICOLA, AQUASCI, BIOTECHNO, COMPENDEX, COMPUAB, CONF, CONFSCI, ELCOM, HEALSAFE, IMSDRUGCONF, LIFESCI, MEDICONF, OCEAN, PAPERCHEM2, PASCAL, POLLUAB, SOLIDSTATE, ADISCTI, ADISINSIGHT, ADISNEWS, ANABSTR, ANTE, AQUALINE, BIOBUSINESS, ...' ENTERED AT 09:56:06 ON 22 NOV 2004

E PILLARISETTI SIVARAM ?/AU

L1 130 S E1 OR E2 OR E3

22718 S PERLECAN OR HSPG OR SYNDECAN OR GLYPICAN

52 S L1 AND L2

L4 27 DUP REM L3 (25 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 10:11:25 ON 22 NOV 2004

FILE 'DISSABS, 1MOBILITY, AGRICOLA, AQUASCI, BIOTECHNO, COMPENDEX, COMPUAB, CONF, CONFSCI, ELCOM, HEALSAFE, IMSDRUGCONF, LIFESCI, MEDICONF, OCEAN, PAPERCHEM2, PASCAL, POLLUAB, SOLIDSTATE, ADISCTI, ADISINSIGHT, ADISNEWS, ANABSTR, ANTE, AQUALINE, BIOBUSINESS, ...' ENTERED AT 10:26:44 ON 22 NOV 2004

8520 S L2 (S) (GROWTH? OR PROLIFERAT? OR ANTIPROLIFER? OR DEATH OR

2352 S L5 (S) (IDENTIF? OR SCREEN? OR MODULAT?)

L7 88 S L6 (S) PRODUCTION

L8 49 DUP REM L7 (39 DUPLICATES REMOVED)

BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN ANSWER 39 OF 49 L8

DUPLICATE

1993:23239744 ACCESSION NUMBER:

BIOTECHNO

TITLE:

Novel neurite growth-inhibitory properties of an

astrocyte proteoglycan

AUTHOR:

Guo M.; Dow K.E.; Kisilevsky R.; Riopelle R.J.

CORPORATE SOURCE:

Doran 2, Kingston General Hospital, Kingston, Ont. K7L

2V7, Canada.

SOURCE:

Journal of Chemical Neuroanatomy, (1993), 6/4

(239-245)

CODEN: JCNAEE ISSN: 0891-0618

DOCUMENT TYPE:

Journal; Article

**COUNTRY:** 

United Kingdom

LANGUAGE:

English

SUMMARY LANGUAGE:

English

Conditioned medium (CM) of primary cultures of GFAP-positive adherent AB astrocytes from neonatal rat neocortex contained a chondroitin sulphate/dermatan sulphate proteoglycan (CDSPG) that co-eluted with a heparan sulphate proteoglycan (HSPG) by ion-exchange chromatography. The CDSPG was resolved from the HSPG by molecular sieve chromatography, which indicated that the molecular mass of the HSPG was greater than 300 kDa, while that of the CDSPG was approximately 50 kDa. Specific lyase digestion and urea/polyacrylamide gel electrophoresis established the ; homogeneity of the CDSPG and suggested molecular masses of the core protein and glycosylated protein as 54 kDa and 58 kDa respectively. Virtually all of the poly-D-lysine substrate-bound proteoglycan-associated neurite growth-promoting activity of astrocyte CM was accounted for by the HSPG. On poly-D-lysine the immobilized CDSPG displayed little neurite growth-stimulatory activity relative to the HSPG. However, the CDSPG inhibited the potent growth -promoting activity of the HSPG by displacing it from the poly-D-lysine substrate. Differential cellular regulation of production of growth-modulatory proteins with different binding avidity for the substrate of growth may determine the success of a regenerative axonal response by fully competent neurons.

AB.

adherent astrocytes from neonatal rat neocortex contained a chondroitin sulphate/dermatan sulphate proteoglycan (CDSPG) that co-eluted with a heparan sulphate proteoglycan (HSPG) by ion-exchange chromatography. The CDSPG was resolved from the HSPG by molecular sieve chromatography, which indicated that the molecular mass of the HSPG was greater than 300 kDa, while that of the CDSPG was approximately 50 kDa. Specific lyase digestion and urea/polyacrylamide gel. . . core protein and glycosylated protein as 54 kDa and 58 kDa respectively. Virtually all of the poly-D-lysine substrate-bound proteoglycan-associated neurite growth -promoting activity of astrocyte CM was accounted for by the HSPG . On poly-D-lysine the immobilized CDSPG displayed little neurite growth-stimulatory activity relative to the HSPG. However, the CDSPG inhibited the potent growth-promoting activity of the HSPG by displacing it from the poly-D-lysine substrate. Differential cellular regulation of production of growth-modulatory proteins with different binding avidity for the substrate of growth may determine the success of a regenerative axonal response by fully competent neurons.

L4 ANSWER 24 OF 27 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. or STN

ACCESSION NUMBER: 2000:20752 BIOSIS DOCUMENT NUMBER: PREV200000020752

TITLE: Perlecan, heparan sulfate proteoglycan, mediates

the anti-proliferative effect of apolipoprotein E: An underlying mechanism for the modulation of smooth muscle

cell growth?.

AUTHOR(S): Paka, Latha [Reprint author]; Obunike, Joseph C.; Choi,

Sungshin Y.; Pillarisetti, Sivaram

CORPORATE SOURCE: North Shore - Long Island Jewish Health System, Manhasset,

NY, USA

SOURCE: Circulation, (Nov. 2, 1999) Vol. 100, No. 18 SUPPL., pp.

I.548. print.

Meeting Info.: 72nd Scientific Sessions of the American Heart Association. Atlanta, Georgia, USA. November 7-10,

1999.

CODEN: CIRCAZ. ISSN: 0009-7322.

DOCUMENT TYPE: Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 29 Dec 1999

Last Updated on STN: 31 Dec 2001

Perlecan, heparan sulfate proteoglycan, mediates the anti-proliferative effect of apolipoprotein E: An underlying mechanism for the modulation of smooth muscle cell. . .

AU Paka, Latha [Reprint author]; Obunike, Joseph C.; Choi, Sungshin Y.; Pillarisetti, Sivaram

regulation

IT Chemicals & Biochemicals

apolipoprotein E: antiproliferative effects, heparan sulfate proteoglycan mediation, smooth muscle cell expression; heparan sulfate proteoglycan [perlecan]: cell proliferation regulator, smooth muscle cell expression

ANSWER 27 OF 27 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

ACCESSION NUMBER: 199 DOCUMENT NUMBER: PRI

1997:434240 BIOSIS PREV199799733443

TITLE:

Subendothelial retention of lipoprotein (a). Evidence that

reduced heparan sulfate promotes lipoprotein binding to

subendothelial matrix.

AUTHOR(S):

Pillarisetti, Sivaram [Reprint author]; Paka,

Latha; Obunike, Joseph C.; Berglund, Lars; Goldberg, Ira J.

CORPORATE SOURCE:

Dep. Med., Columbia Univ. Coll. Physicians Surgeons, BB

901, 630 West 168th St., New York, NY 10032, USA

SOURCE:

AB.

Journal of Clinical Investigation, (1997) Vol. 100, No. 4,

pp. 867-874.

CODEN: JCINAO. ISSN: 0021-9738.

DOCUMENT TYPE:

Article English

LANGUAGE: ENTRY DATE:

Entered STN: 8 Oct 1997

Last Updated on STN: 8 Oct 1997

Vessel wall subendothelial extracellular matrix, a dense mesh formed of AB collagens, fibronectin, laminin, and proteoglycans, has important roles in lipid and lipoprotein retention and cell adhesion. In atherosclerosis, vessel wall heparan sulfate proteoglycans (HSPG) are decreased and we therefore tested whether selective loss of HSPG affects lipoprotein retention. A matrix synthesized by aortic endothelial cells and a commercially available matrix (Matrigel; Becton Dickinson Inc., Rutherford, NJ) were used. Treatment of matrix with heparinase/heparitinase (1 U/ml each) increased LDL binding by apprx 1.5-fold. Binding of lipoprotein (a) (Lp(a)) to both subendothelial matrix and Matrigel increased 2-10-fold when the HSPG were removed by heparinase treatment. Incubation of endothelial cells with oxidized LDL (OxLDL) or lysolecithin resulted in decreased matrix proteoglycans and increased Lp(a) retention by matrix. The effect of OxLDL or lysolecithin on endothelial PG was abolished in the presence of The decrease in matrix HSPG was associated with production of a heparanase-like activity by OxLDL-stimulated endothelial cells. test whether removal of HSPG exposes fibronectin, a candidate Lp(a) binding protein in the matrix, antifibronectin antibodies were used. The increased Lp(a) binding after HSPG removal was inhibited 60% by antifibronectin antibodies. Similarly, the increased Lp(a) binding to matrix from OxLDL-treated endothelial cells was inhibited by antifibronectin antibodies. We hypothesize that atherogenic lipoproteins stimulate endothelial cell production of heparanase. This enzyme reduces HSPG which in turn promotes Lp(a) retention.

AU Pillarisetti, Sivaram [Reprint author]; Paka, Latha; Obunike, Joseph C.; Berglund, Lars; Goldberg, Ira J.

. . and proteoglycans, has important roles in lipid and lipoprotein retention and cell adhesion. In atherosclerosis, vessel wall heparan sulfate proteoglycans (HSPG) are decreased and we therefore tested whether selective loss of HSPG affects lipoprotein retention. A matrix synthesized by aortic endothelial cells and a commercially available matrix (Matrigel; Becton Dickinson Inc., Rutherford, . . LDL binding by apprx 1.5-fold. Binding of lipoprotein (a) (Lp(a)) to both subendothelial matrix and Matrigel increased 2-10-fold when the HSPG were removed by heparinase treatment. Incubation of endothelial cells with oxidized LDL (OxLDL) or lysolecithin resulted in decreased matrix proteoglycans. . . The effect of OxLDL or lysolecithin on endothelial PG was abolished in the presence of HDL. The decrease in matrix HSPG was associated with production of a heparanase-like activity by OxLDL-stimulated endothelial cells. To test whether removal of HSPG exposes fibronectin, a candidate Lp(a) binding protein in the matrix, antifibronectin antibodies were used. The increased Lp(a) binding after HSPG removal was inhibited 60% by antifibronectin antibodies. Similarly, the increased Lp(a) binding to matrix from OxLDL-treated endothelial cells was inhibited by antifibronectin 



Creation date: 11-30-2004

Indexing Officer: NKIDANE - NIGIST M. KIDANE

Team: OIPEScanning Dossier: 10763413

Legal Date: 11-30-2004

Total number of pages: 9

No.	Doccode	Number of pages
1	CTRS	7
2	BIB	1
3	FWCLM	1

	•		
Remarks:			
•			
Order of re-sca	an issued c	on	